Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022)
JCO Global Oncology · 2026
DOI: 10.1200/go-25-00411 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Rodrigo Paredes de la Fuente und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai West/Morningside, New York, NY. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Neoplasms, Medical Oncology. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Latin America (LATAM), home to over 650 million people, remains under-represented in global oncology trials despite a growing cancer burden. This study aimed to evaluate the evolution of LATAM participation in phase III oncology trials over the past decade, with a focus on site distribution, cancer types studied, therapeutic classes investigated, and demographic reporting. METHODS We conducted a cross-sectional analysis of global phase III oncology trials registered on ClinicalTrials.gov between January 1, 2013, and December 31, 2022. Trials were included if they studied anticancer therapies and listed at least one LATAM site. We extracted data on trial geography, cancer type, treatment modality, control group, and Hispanic ethnicity reporting. Trends in proportional regional site representation and therapy class were assessed using the Mann-Kendall trend test. RESULTS A total of 172 phase III trials with LATAM sites were identified, representing 2,609 of 29,718 global sites (8.8%). Brazil (45.8%), Argentina (18.6%), and Mexico (13.0%) accounted for over 75% of LATAM trial sites. LATAM's proportional site representation increased modestly from 7.1% in 2013 to 9.3% in 2021 (Bonferroni-adjusted P = .040), but no individual country showed a statistically significant increase. The most frequently studied cancers were lung (26.7%), breast (22.1%), and genitourinary (16.3%). Targeted therapies (42.4%) and immunotherapies (33.1%) dominated, whereas hormone therapy declined over time. Hispanic ethnicity was reported in only 61.6% of trials, with no improvement over time. CONCLUSION Although LATAM's participation in global oncology trials has increased, it remains geographically concentrated and demographically under-reported. Structural and policy efforts are needed to improve trial equity and align research with regional cancer burdens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai West/Morningside, New York, NY.
- Universidad de San Martín de Porres, Facultad de Medicina Humana, Lima, Peru.
- Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
- Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY.
- Icahn School of Medicine at Mount Sinai, New York, NY.
- Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
ORCID-Profile: Rodrigo Paredes de la Fuente, Alexander B Karol, Anneliese Markus, Yu Fujiwara, Himanshu Joshi, Deborah B Doroshow, Matthew D Galsky
Zitieren
APA
Paredes de la Fuente, R., Karol, A. B., Markus, A., Argulian, A., Omori, R., Fujiwara, Y., Joshi, H., Doroshow, D. B., & Galsky, M. D. (2026). Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022). JCO Global Oncology. https://doi.org/10.1200/go-25-00411
Vancouver
Paredes de la Fuente R, Karol AB, Markus A, Argulian A, Omori R, Fujiwara Y, et al. Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022). JCO Global Oncology. 2026. doi:10.1200/go-25-00411
BibTeX
@article{ParedesdelaFuente2026,
author = {Paredes de la Fuente, Rodrigo and Karol, Alexander B and Markus, Anneliese and Argulian, Anna and Omori, Reo and Fujiwara, Yu and Joshi, Himanshu and Doroshow, Deborah B and Galsky, Matthew D},
title = {Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022)},
journal = {JCO Global Oncology},
year = {2026},
doi = {10.1200/go-25-00411}
}
EUVIMED